首頁 > 市場調查報告書 > 製藥

循環系統

全球充血性心臟衰竭藥物市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

市場調查報告書

商品編碼

1377872

全球充血性心臟衰竭藥物市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

Global Congestive Heart Failure Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年09月01日 | 出版商:

Value Market Research | 英文 143 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球充血性心臟衰竭藥物市場需求預計將從 2022 年的 72.9 億美元達到 2030 年近 242.8 億美元的市場規模，2023-2030 年研究期間CAGR為 16.23%。

充血性心臟衰竭(CHF) 藥物，也稱為心臟衰竭藥物或心臟藥物，是一類用於管理和治療充血性心臟衰竭的藥物。充血性心臟衰竭是一種慢性疾病，患者的心臟停止有效泵血以滿足身體的需要。它可能由各種潛在原因引起，例如冠狀動脈疾病、高血壓、心臟瓣膜疾病或心肌病變。

市場動態：

心臟衰竭發生率的增加通常與老化和生活方式因素有關，這推動了對充血性心臟衰竭藥物的需求。隨著全球人口老化，心臟衰竭風險較高的老年人口數量增多，進一步推動了這項需求。藥物治療的進步，包括新藥物和聯合療法的開發，正在加強心臟衰竭的治療。醫療保健提供者和患者意識的提高以及監管支持促進了 CHF 藥物的採用。植入式心臟設備和遠距醫療等技術進步補充了藥物治療並改善了患者護理。個人化醫療根據個人情況定製藥物治療方案，最佳化治療結果。研究、臨床試驗和合作繼續推動慢性心臟衰竭藥物開發的創新，重點是改善患者的治療結果和生活品質。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球充血性心臟衰竭藥物市場的各個細分市場進行了包容性評估。充血性心臟衰竭藥物產業的成長和趨勢為本研究提供了整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲充血性心臟衰竭藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。充血性心臟衰竭藥物市場的主要參與者包括拜耳公司、諾華公司、默克公司、阿斯特捷利康公司、百時美施貴寶公司、安進公司、勃林格殷格翰國際有限公司、輝瑞公司、強生公司Services , Inc.、大塚製藥有限公司、禮來公司、諾和諾德公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：充血性心臟衰竭藥品公司的競爭格局

充血性心臟衰竭藥物市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Bayer AG

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

Merck & Co. Inc.

公司簡介
公司收入
產品
最近的發展

AstraZeneca

公司簡介
公司收入
產品
最近的發展

Bristol-Myers Squibb Company

公司簡介
公司收入
產品
最近的發展

Amgen Inc.

公司簡介
公司收入
產品
最近的發展

Boehringer Ingelheim International GmbH

公司簡介
公司收入
產品
最近的發展

Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Johnson & Johnson Services Inc.

公司簡介
公司收入
產品
最近的發展

Otsuka Pharmaceutical Co. Ltd.

公司簡介
公司收入
產品
最近的發展

Eli Lilly and Company

公司簡介
公司收入
產品
最近的發展

Novo Nordisk A/S.

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112112245

The global demand for Congestive Heart Failure Drugs Market is presumed to reach the market size of nearly USD 24.28 BN by 2030 from USD 7.29 BN in 2022 with a CAGR of 16.23% under the study period 2023 - 2030.

Congestive Heart Failure (CHF) drugs, also known as heart failure medications or cardiac medications, are a class of pharmaceuticals used to manage and treat congestive heart failure-a chronic medical condition in which the heart stops pumping blood effectively to meet the body's needs. It can result from various underlying causes, such as coronary artery disease, hypertension, heart valve disorders, or cardiomyopathy.

MARKET DYNAMICS:

The increasing incidence of heart failure, often associated with aging and lifestyle factors, is driving the demand for congestive heart failure medications. As the global population ages, a larger demographic of elderly individuals at higher risk of heart failure further contributes to this demand. Advancements in drug therapies, including the development of new medications and combination therapies, are enhancing the management of heart failure. Increased awareness among healthcare providers and patients, along with regulatory support, fosters the adoption of CHF drugs. Technological advancements, such as implantable cardiac devices and telemedicine, complement drug therapies and improve patient care. Personalized medicine tailors drug regimens to individual profiles, optimizing treatment outcomes. Research, clinical trials, and collaborations continue to drive innovation in CHF drug development, focusing on improving patient outcomes and quality of life.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of congestive heart failure drugs. The growth and trends of congestive heart failure drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the congestive heart failure drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

ACE Inhibitors
Angiotensin 2 Receptor Blockers
Beta Blockers
Diuretics
Aldosterone Antagonists
Inotropes
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Congestive Heart Failure Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Congestive Heart Failure Drugs market include Bayer AG, Novartis AG, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim International GmbH, Pfizer, Inc., Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Novo Nordisk A/S. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . CONGESTIVE HEART FAILURE DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Distribution Channel
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 ACE Inhibitors Historic and Forecast Sales by Regions
5.5 Angiotensin 2 Receptor Blockers Historic and Forecast Sales by Regions
5.6 Beta Blockers Historic and Forecast Sales by Regions
5.7 Diuretics Historic and Forecast Sales by Regions
5.8 Aldosterone Antagonists Historic and Forecast Sales by Regions
5.9 Inotropes Historic and Forecast Sales by Regions
5.10. Others Historic and Forecast Sales by Regions

6 . GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

6.1 Overview by Distribution Channel
6.2 Historical and Forecast Data
6.3 Analysis by Distribution Channel
6.4 Hospital Pharmacies Historic and Forecast Sales by Regions
6.5 Retail Pharmacies Historic and Forecast Sales by Regions
6.6 Online Pharmacies Historic and Forecast Sales by Regions

7 . GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE CONGESTIVE HEART FAILURE DRUGS COMPANIES

8.1. Congestive Heart Failure Drugs Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF CONGESTIVE HEART FAILURE DRUGS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Bayer AG
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Novartis AG
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Merck & Co. Inc.
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. AstraZeneca
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Bristol-Myers Squibb Company
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Amgen Inc.
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Boehringer Ingelheim International GmbH
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. Pfizer Inc.
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Johnson & Johnson Services Inc.
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
9.12. Otsuka Pharmaceutical Co. Ltd.
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments
9.13. Eli Lilly and Company
- 9.13.1. Company Overview
- 9.13.2. Company Revenue
- 9.13.3. Products
- 9.13.4. Recent Developments
9.14. Novo Nordisk A/S.
- 9.14.1. Company Overview
- 9.14.2. Company Revenue
- 9.14.3. Products
- 9.14.4. Recent Developments